ImmunoPrecise Antibodies Ltd. (IPA)
- Previous Close
1.2400 - Open
1.2300 - Bid 1.1600 x 100
- Ask 1.3000 x 100
- Day's Range
1.2250 - 1.2700 - 52 Week Range
0.9400 - 4.2200 - Volume
23,251 - Avg. Volume
607,337 - Market Cap (intraday)
32.236M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4700 - Earnings Date Jul 5, 2024 - Jul 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.02
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.
www.ipatherapeutics.comRecent News: IPA
Performance Overview: IPA
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IPA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IPA
Valuation Measures
Market Cap
32.89M
Enterprise Value
35.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.91
Price/Book (mrq)
0.87
Enterprise Value/Revenue
1.57
Enterprise Value/EBITDA
-3.43
Financial Highlights
Profitability and Income Statement
Profit Margin
-60.22%
Return on Assets (ttm)
-10.98%
Return on Equity (ttm)
-25.72%
Revenue (ttm)
23.68M
Net Income Avi to Common (ttm)
-14.26M
Diluted EPS (ttm)
-0.4700
Balance Sheet and Cash Flow
Total Cash (mrq)
6.2M
Total Debt/Equity (mrq)
28.89%
Levered Free Cash Flow (ttm)
-858k